

Global Idiopathic Pulmonary Fibrosis (IPF) Market – Analysis By Drug Type, End User, By Region, By Country (2021 Edition): Market Insights, Pipeline and Forecast with Impact of COVID-19 (2021-2026)

<https://marketpublishers.com/r/G60FD1CC58A0EN.html>

Date: December 2021

Pages: 220

Price: US\$ 2,400.00 (Single User License)

ID: G60FD1CC58A0EN

Abstracts

Executive Summary

According to Azoth Analytics research report, the global Idiopathic Pulmonary Fibrosis Market is projected to display robust growth valued at USD 3271.3 Million in the year 2020 with North America leading the regional market share.

The primary driver of growth in the IPF market in recent years has been an increased use of the high-priced Pirfenidone (Esbriet) and Nintedanib (Ofev) brands in favour of off-label pharmacological therapies and non-pharmacological treatments. Prior to the approval of these drugs, cheap corticosteroids and immunosuppressant's were used to treat IPF despite negative recommendations in evidence-based guidelines for general treatment.

The major factors that drive the growth of the global idiopathic pulmonary fibrosis market include a rise in the prevalence of fibrotic disease and an increase in the geriatric population. In addition, a surge in demand for cost-effective drugs and the introduction of advanced treatment options propel market growth. Furthermore, changing lifestyle patterns and increasing consumption of nicotine products is providing a thrust to the market growth. Moreover, smoking tobacco and cigarettes are considered the most common cause for the development of IPF. In line with this, increasing health consciousness among the masses regarding the effective management strategies of IPF is also favouring the growth of the market.

Additionally, the advent of novel medicines and advancements in the IPF diagnostic and treatment methods, are acting as other growth-inducing factors. This, along with extensive research and development (R&D) activities and improvements in the healthcare infrastructure, represents some of the other factors anticipated to drive the market.

Moreover, to pharmacological treatments, various non-pharmacological treatments are also used for IPF patients. The most used non-pharmacological treatments are lung transplantations, mechanical ventilation, oxygen therapy, and pulmonary rehabilitation. In general, the treatment approach in IPF is largely dependent on a patient's symptoms, the stage of the disease, and a patient's overall health.

Scope of the Report

The report presents the analysis of the Idiopathic Pulmonary Fibrosis market for the historical period of 2016-2020 and the forecast period of 2021-2026.

The report analyses the Idiopathic Pulmonary Fibrosis Market by Value (USD Million).

The report analyses the Idiopathic Pulmonary Fibrosis Market by Drug Type (Nintedanib, Pirfenidone, Others).

The report analyses the Idiopathic Pulmonary Fibrosis Market by End User (Hospital & Clinics, Academic and Research Organizations, Others).

The Global Idiopathic Pulmonary Fibrosis Market has been analysed By Region (North America, Europe, Asia Pacific).

The Global Idiopathic Pulmonary Fibrosis Market has been analysed By Country (United States, Canada, Germany, France, United Kingdom, Spain, Italy, China, Japan, India).

The attractiveness of the market has been presented by region, by Drug Class and by End User.

Also, the major opportunities, trends, drivers and challenges of the industry have been analysed in the report.

The report tracks competitive developments, strategies, mergers and acquisitions and new product development.

The companies analysed in the report include AbbVie Inc., Bristol-Myers Squibb, F. Hoffman-La Roche, Ltd., Boehringer Ingelheim, Merck KGaA, Gilead Sciences, Liminal Biosciences, Cipla, Galapagos NV, FibroGen, Medicinova Inc.

Key Target Audience

Pharmaceutical and Healthcare Companies

Consulting and Advisory Firms

Government and Policy Makers

Regulatory Authorities

Contents

1. REPORT SCOPE AND METHODOLOGY

- 1.1 Scope of the Report
- 1.2 Research Methodology
- 1.3 Executive Summary

2. STRATEGIC RECOMMENDATIONS

3. IDIOPATHIC PULMONARY FIBROSIS MARKET: PRODUCT OUTLOOK

4. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET: SIZING AND FORECAST

- 4.1 Global Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026
- 4.2 Impact of COVID-19 on Global Idiopathic Pulmonary Fibrosis Market

5. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SEGMENTATION - BY DRUG TYPE, BY END USER

- 5.1 Competitive Scenario of Global Idiopathic Pulmonary Fibrosis Market: By Drug Type
 - 5.1.1 Nintedanib - Market Size and Forecast (2016-2026)
 - 5.1.2 Pirfenidone - Market Size and Forecast (2016-2026)
 - 5.1.3 Others - Market Size and Forecast (2016-2026)
- 5.2 Competitive Scenario of Global Idiopathic Pulmonary Fibrosis Market: By End User
 - 5.2.1 Hospitals and Clinics - Market Size and Forecast (2016-2026)
 - 5.2.2 Academics and Research Organization - Market Size and Forecast (2016-2026)
 - 5.2.3 Others - Market Size and Forecast (2016-2026)

6. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET: REGIONAL ANALYSIS

- 6.1 Competitive Scenario of Global Idiopathic Pulmonary Fibrosis Market: By Region

7. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET: AN ANALYSIS (2016-2026)

- 7.1 North America Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value

- 7.2 North America Idiopathic Pulmonary Fibrosis Market - Prominent Companies
- 7.3 Market Segmentation By Drug Type (Nintedanib, Pirfenidone and Others)
- 7.4 Market Segmentation By End User (Hospitals and Clinics, Academics and Research Organization and Others)
- 7.5 North America Idiopathic Pulmonary Fibrosis Market: Country Analysis
- 7.6 Market Opportunity Chart of North America Idiopathic Pulmonary Fibrosis Market - By Country, By Value, 2026
- 7.7 Competitive Scenario of North America Idiopathic Pulmonary Fibrosis Market: By Country
- 7.8 United States Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
- 7.9 United States Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
- 7.10 Canada Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
- 7.11 Canada Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)

8. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET: AN ANALYSIS (2016-2026)

- 8.1 Europe Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
- 8.2 Europe Idiopathic Pulmonary Fibrosis Market - Prominent Companies
- 8.3 Market Segmentation By Drug Type (Nintedanib, Pirfenidone, Others)
- 8.4 Market Segmentation By End User (Hospitals and Clinics, Academics and Research Organization, Others)
- 8.5 Europe Idiopathic Pulmonary Fibrosis Market: Country Analysis
- 8.6 Market Opportunity Chart of Europe Idiopathic Pulmonary Fibrosis Market - By Country, By Value, 2026
- 8.7 Competitive Scenario of Europe Idiopathic Pulmonary Fibrosis Market: By Country
- 8.8 Germany Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
- 8.9 Germany Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
- 8.10 United Kingdom Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
- 8.11 United Kingdom Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)

8.12 France Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value

8.13 France Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)

8.14 Italy Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value

8.15 Italy Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)

8.16 Spain Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value

8.17 Spain Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)

9. ASIA PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET: AN ANALYSIS (2016-2026)

9.1 Asia Pacific Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value

9.2 Asia Pacific Idiopathic Pulmonary Fibrosis Market - Prominent Companies

9.3 Market Segmentation By Drug Type (Nintedanib, Pirfenidone, Others)

9.4 Market Segmentation By End User (Hospitals and Clinics, Academics and Research Organization, Others)

9.5 Asia Pacific Idiopathic Pulmonary Fibrosis Market: Country Analysis

9.6 Market Opportunity Chart of Asia Pacific Idiopathic Pulmonary Fibrosis Market - By Country, By Value, 2026

9.7 Competitive Scenario of Asia Pacific Idiopathic Pulmonary Fibrosis Market: By Country

9.8 China Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value

9.9 China Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)

9.10 Japan Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value

9.11 Japan Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)

9.12 India Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value

9.13 India Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)

10. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET DYNAMICS

- 10.1 Drivers
- 10.2 Restraints
- 10.3 Trends

11. MARKET ATTRACTIVENESS

- 11.1 Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market - By Drug Type, 2026
- 11.2 Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market - By End User, 2026
- 11.3 Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market - By Region, 2026

12. COMPETITIVE LANDSCAPE

- 12.1 Product Pipeline of Leading Idiopathic Pulmonary Fibrosis Companies
- 12.2 Market Share Analysis

13. COMPANY ANALYSIS

- 13.1 AbbVie Inc.
- 13.2 Bristol-Myers Squibb
- 13.3 F. Hoffman-La Roche Ltd.
- 13.4 Boehringer Ingelheim
- 13.5 Merck KGaA
- 13.6 Gilead Sciences
- 13.7 Liminal Biosciences
- 13.8 Cipla
- 13.9 Galapagos NV
- 13.10 FibroGen
- 13.11 Medicinova Inc.

Tables & Figures

TABLES AND FIGURES

Figure 1: Global Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)

Figure 2: Global Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 3: GDP per Capita Growth (annual %), 2015-2019

Figure 4: World Population 65 Years & Above (% of Total), 2015-2019

Figure 5: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 6: Global Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)

Figure 7: Global IPF - Number of Drugs by Phase

Figure 8: Global Idiopathic Pulmonary Fibrosis Market- By Drug Type Market Share, 2020 & 2026

Figure 9: Global Idiopathic Pulmonary Fibrosis Market- By Nintedanib, By Value (USD Million), 2016-2026

Figure 10: Global Idiopathic Pulmonary Fibrosis Market- By Pirfenidone, By Value (USD Million), 2016-2026

Figure 11: Global Idiopathic Pulmonary Fibrosis Market- By Others, By Value (USD Million), 2016-2026

Figure 12: Global Idiopathic Pulmonary Fibrosis Market- By End User Market Share, 2020 & 2026

Figure 13: Global Idiopathic Pulmonary Fibrosis Market- By Hospitals and Clinics, By Value (USD Million), 2016-2026

Figure 14: Global Idiopathic Pulmonary Fibrosis Market- By Academics and Research Organization, By Value (USD Million), 2016-2026

Figure 15: Global Idiopathic Pulmonary Fibrosis Market- By Others, By Value (USD Million), 2016-2026

Figure 16: Global Idiopathic Pulmonary Fibrosis Market- By Region Market Share, 2020 & 2026

Figure 17: North America Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)

Figure 18: North America Current health expenditure(% of GDP)2014-2018

Figure 19: North America Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 20: North America Population ages 65 and above (% of total Population), 2016-2020

Figure 21: North America Idiopathic Pulmonary Fibrosis company market share (%), 2020

Figure 22: North America Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026

Figure 23: North America Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026

Figure 24: Market Opportunity Chart of North America Idiopathic Pulmonary Fibrosis Market- By Country, By Value (Year 2016-2026)

Figure 25: North America Idiopathic Pulmonary Fibrosis Market- By Country Market Share, 2020 & 2026

Figure 26: United States Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)

Figure 27: United States Distribution of Diagnosed IPF Patients, 2020

Figure 28: United States Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 29: United States Population aged 65 and above (% of total Population), 2016-2020

Figure 30: United States Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026

Figure 31: United States Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026

Figure 32: Canada Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)

Figure 33: Canada Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 34: Canada Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 35: Canada Population aged 65 and above (% of total Population), 2016-2020

Figure 36: Canada Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026

Figure 37: Canada Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026

Figure 38: Europe Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)

Figure 39: Europe Distribution of Diagnosed IPF Patients, 2020

Figure 40: Europe Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 41: European Countries Population ages 65 and above (% of total Population), 2020

Figure 42: Europe Idiopathic Pulmonary Fibrosis company market share (%), 2020

Figure 43: Europe Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026

Figure 44: Europe Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD

Million), 2016-2026

Figure 45: Market Opportunity Chart of Europe Idiopathic Pulmonary Fibrosis Market- By Country, By Value (Year 2016-2026)

Figure 46: Europe Idiopathic Pulmonary Fibrosis Market- By Country Market Share, 2020 & 2026

Figure 47: Germany Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)

Figure 48: Germany Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 49: Germany Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 50: Germany Urban population growth,(Annual %) 2015-2020 (In %)

Figure 51: Germany Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026

Figure 52: Germany Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026

Figure 53: United Kingdom Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)

Figure 54: United Kingdom Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 55: United Kingdom Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 56: United Kingdom Population ages 65 and above (% of total Population), 2016-20

Figure 57: United Kingdom Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026

Figure 58: United Kingdom Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026

Figure 59: France Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)

Figure 60: France Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 61: France Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 62: France Population ages 65 and above (% of total Population), 2016-20

Figure 63: France Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026

Figure 64: France Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026

Figure 65: Italy Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)

Figure 66: Italy Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 67: Italy Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 68: Italy Population ages 65 and above (% of total Population), 2016-20

Figure 69: Italy Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026

Figure 70: Italy Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026

Figure 71: Spain Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)

Figure 72: Spain Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 73: Spain Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 74: Spain Urban population Growth (Annual %), 2016-2020 (In %)

Figure 75: Spain Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026

Figure 76: Spain Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026

Figure 77: Asia Pacific Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)

Figure 78: Asia Pacific Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 79: Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 80: Asia Pacific Population ages 65 and above, by Countries (% of total Population), 2020

Figure 81: Asia Pacific Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026

Figure 82: Asia Pacific Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026

Figure 83: Market Opportunity Chart of APAC Idiopathic Pulmonary Fibrosis Market- By Country, By Value (Year-2026)

Figure 84: APAC Idiopathic Pulmonary Fibrosis Market- By Country Market Share, 2020 & 2026

Figure 85: China Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)

Figure 86: China Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 87: China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 88: China Population ages 65 and above (% of total Population), 2016-20

Figure 89: China Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026

Figure 90: China Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026

Figure 91: Japan Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)

Figure 92: Japan Europe Distribution of Diagnosed IPF Patients, 2020

Figure 93: Japan Current Healthcare Expenditure as percentage of GDP, 2015-2018 (In %)

Figure 94: Japan Population ages 65 and above (% of total Population), 2016-20

Figure 95: Japan Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026

Figure 96: Japan Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026

Figure 97: India Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)

Figure 98: India Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 99: India Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 100: India Population ages 65 and above (% of total Population), 2016-20

Figure 101: India Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026

Figure 102: India Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026

Figure 103: Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market- By Drug Type (Year-2016-2026)

Figure 104: Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market- By End User (Year 2016-2026)

Figure 105: Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market- By Region (Year 2016-2026)

Figure 106: Global Idiopathic Pulmonary Fibrosis company market share

Figure 107: AbbVie Inc. Annual Sales Revenue (USD Million), 2016-2020

Figure 108: AbbVie Inc. Net Income (USD Million), 2016-2020

Figure 109: AbbVie Inc. Sales Revenue Split, By Business Segment (%), FY2020

Figure 110: AbbVie Inc. Sales Revenue Split, By Geography Segment (%), FY2020

Figure 111: Bristol-Myers Squibb Sales Revenues, 2016-2020 (USD Million)

Figure 112: Bristol-Myers Squibb Net Income, 2016-2020 (USD Million)

Figure 113: Bristol-Myers Squibb Sales Revenue Split, By Business Segment (%), FY2020

Figure 114: Bristol-Myers Squibb Sales Revenue Split, By Geography Segment (%), FY2020

Figure 115: F. Hoffman-La Roche Ltd. Sales Revenues, 2016-2020 (USD Million)

Figure 116: F. Hoffman-La Roche Ltd. Net Income, 2016-2020 (USD Million)

Figure 117: F. Hoffman-La Roche Ltd. sales Revenues, By Business Segment (%),

FY2020

Figure 118: F. Hoffman-La Roche Ltd. sales Revenue, By Geographical Segment (%), FY2020

Figure 119: Boehringer Ingelheim Revenues, 2016-2020 (USD Million)

Figure 120: Boehringer Ingelheim Net Income/Loss, 2016-2020 (USD Million)

Figure 121: Boehringer Ingelheim Sales Revenue Split, By Business Segment (%), FY2020

Figure 122: Boehringer Ingelheim Sales Revenue Split, By Geography Segment (%), FY2020

Figure 123: Merck KGaA Sales Revenues, 2016-2020 (USD Million)

Figure 124: Merck KGaA Gross Profit, 2016-2020 (USD Million)

Figure 125: Merck KGaA Sales Revenue Split, By Business Segment (%), FY2020

Figure 126: Merck KGaA Sales Revenue Split, By Geography Segment (%), FY2020

Figure 127: Gilead Sciences, Revenue, 2016-2020 (USD Million)

Figure 128: Gilead Sciences, Net Income 2016-2020 (USD Million)

Figure 129: Gilead Sciences, Revenue, By Business Segment (%), FY2020

Figure 130: Gilead Sciences Revenue, By Geographical Segment (%), FY2020

Figure 131: Liminal Biosciences, Revenue, 2016-2020 (USD Million)

Figure 132: Liminal Biosciences, Net Loss 2016-2020 (USD Million)

Figure 133: Liminal Biosciences, Revenue, By Business Segment (%), FY2020

Figure 134: Liminal Biosciences Revenue, By Geographical Segment (%), FY2020

Figure 135: Cipla Sales Revenues, 2016-2020 (USD Million)

Figure 136: Cipla sales Revenues, By Business Segment (%), FY2020

Figure 137: Cipla sales Revenue, By Geographical Segment (%), FY2020

Figure 138: Galapagos NV Annual Sales Revenue (USD Million), 2016-2020

Figure 139: Galapagos NV sales Revenue, By Geographical Segment (%), FY2020

Figure 140: FibroGen, Revenue, 2016-2020 (USD Million)

Figure 141: FibroGen, Net Loss 2016-2020 (USD Million)

Figure 142: MediciNova, Inc., Total Operating Expenses, 2015-2019 (USD Million)

Figure 143: MediciNova Inc., Net Loss 2015-2019 (USD Million)

Table A Product Pipeline of Leading Idiopathic Pulmonary Fibrosis Companies

Table B Product Pipeline of Leading Idiopathic Pulmonary Fibrosis Companies

Table C Product Pipeline of Leading Idiopathic Pulmonary Fibrosis Companies

Table D Product Pipeline of Leading Idiopathic Pulmonary Fibrosis Companies - Vicore Pharma

Table E Deals in IPF and severe cough

I would like to order

Product name: Global Idiopathic Pulmonary Fibrosis (IPF) Market – Analysis By Drug Type, End User, By Region, By Country (2021 Edition): Market Insights, Pipeline and Forecast with Impact of COVID-19 (2021-2026)

Product link: <https://marketpublishers.com/r/G60FD1CC58A0EN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G60FD1CC58A0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970